Clinical Trial Update: A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor [Phase 3]

View source ↗

Summary

Phase 3 study evaluating tezacaftor in combination with ivacaftor in CF patients aged 12+ with one F508del-CFTR mutation and a responsive second mutation; trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (VX-770) (ivacaftor)
• Tezacaftor (VX-661) (tezacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2019-01-08